# Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02229227` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02229227](<https://clinicaltrials.gov/study/NCT02229227>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02229227

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 814 participants.

## Technical summary

Registry record NCT02229227. Randomized; no masking; primary purpose treatment. Start 2014-11-21 (actual); primary completion 2017-07-24 (actual). Results posted on 2018-06-29.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 814 participants (enrolled count; ClinicalTrials.gov record NCT02229227, source copy `cardio:ctgov-nct02229227-2020-11-27`, retrieved 2026-10-26)
- Started: 2014-11-21 (actual) (ClinicalTrials.gov record NCT02229227, source copy `cardio:ctgov-nct02229227-2020-11-27`, retrieved 2026-10-26)
- Primary completion: 2017-07-24 (actual) (ClinicalTrials.gov record NCT02229227, source copy `cardio:ctgov-nct02229227-2020-11-27`, retrieved 2026-10-26)
- Completion: 2017-07-24 (actual) (ClinicalTrials.gov record NCT02229227, source copy `cardio:ctgov-nct02229227-2020-11-27`, retrieved 2026-10-26)
- Results first posted: 2018-06-29 (ClinicalTrials.gov record NCT02229227, source copy `cardio:ctgov-nct02229227-2020-11-27`, retrieved 2026-10-26)
- Countries: United States; Brazil; Canada; France; Germany; Hungary; Italy; Mexico; Philippines; Poland; South Africa; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT02229227, source copy `cardio:ctgov-nct02229227-2020-11-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02229227-2020-11-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Albiglutide
- Intervention (Drug): Insulin Glargine and Insulin Lispro
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY
- Collaborator: PPD Development, LP
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)
- Registry lists this organization as a collaborator: PPD Development, LP (`cardio:org-ppd-development-lp`)

## Provenance

Content hash: ce5f882cf03b7be5451187914ab17528c76c0d8c4a6bab3a3917118ae79c9eea
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
